Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023

HR 2639 requires Medicare to only pay for nerve conduction studies and needle electromyography tests (electrodiagnostic services) provided at "qualified facilities" starting 3-4 years after enactment. A qualified facility must be accredited by an organization approved by the Secretary of Health and Human Services and meet specific standards, including having a quality program, using approved equipment, ensuring staff have adequate training, and requiring on-site interpretation of results during the procedure. The bill also mandates the Secretary to establish an advisory committee to recommend standards for accreditation and quality improvements in these services. This affects facilities providing electrodiagnostic testing and aims to standardize care through accreditation requirements.